Show simple item record

dc.contributor.authorCrabtree, Thomas
dc.contributor.authorIdris, Iskandar
dc.date.accessioned2022-05-11T14:52:35Z
dc.date.available2022-05-11T14:52:35Z
dc.identifier.citationDiabetes Obes Metab. 2022 Mar 23. doi: 10.1111/dom.14701. Online ahead of print.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12904/15412
dc.description.abstractThe ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work demonstrated differential reductions in HbA1c and weight dependent on previous GLPRA exposure. The analysis, in this research letter, demonstrates decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide - potentially suggesting differing potencies between GLP1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings. This article is protected by copyright. All rights reserved.
dc.language.isoenen_US
dc.subjectGLP-1 Analogueen_US
dc.subjectObservational Studyen_US
dc.subjectType 2 Diabetesen_US
dc.titleInjectable semaglutide and reductions in HbA1c and weight in the real-world in people switched from alternative glucagon-like peptide 1 receptor agonists.en_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
refterms.dateFirstOnline2022-03
html.description.abstractThe ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work demonstrated differential reductions in HbA1c and weight dependent on previous GLPRA exposure. The analysis, in this research letter, demonstrates decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide - potentially suggesting differing potencies between GLP1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings. This article is protected by copyright. All rights reserved.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record